Undisclosed BeCMs based bispecific TCE / Be Biopharma - LARVOL DELTA

Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting (Businesswire) - "Be Biopharma...announced that it will present new data from preclinical research and collaboration programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023....Data selected for oral presentation from late-breaking abstract from NIH-partnered study showing engraftment without preconditioning in non-human primates. Engineered B cells demonstrate in vivo anti-tumor efficacy with bi-specific T cell engagers. Additional studies demonstrate precise engineering and expression of multiple therapeutic proteins."

Late-breaking abstract • Preclinical • Oncology